Newsfeeds - Spark Newswire

3 minute read

36 Stocks Moving In Wednesday’s Mid-Day Session

Today, 8:36 PM

Gainers Nxt-ID, Inc. (NASDAQ: NXTD) shares gained 28.9% to $3.21 after the company said it was awarded U.S. General Services Administration contract to distribute personal emergency response systems to Federal, State and Local government purchasers.

ABM

3 minute read

20 Stocks Moving in Wednesday’s Pre-Market Session

By Lisa Levin

Today, 8:36 PM

Gainers

ADGI

2 minute read

Movers

12 Health Care Stocks Moving In Tuesday’s Intraday Session

By Benzinga Insights

Today, 8:36 PM

Gainers

ADAG

3 minute read

34 Stocks Moving In Tuesday’s Mid-Day Session

By Lisa Levin

Today, 8:36 PM

Gainers Exicure, Inc. (NASDAQ: XCUR) rose 41.8% to $0.3830. Exicure’s Audit Committee recently concluded that Grant Corbett misreported raw data from certain R&D experiments related to XCUR-FXN preclinical program.

ADGI

1 minute read

Why Mesoblast Shares Are Falling

By Henry Khederian

Today, 8:36 PM

Mesoblast Limited (NASDAQ: MESO) shares are trading lower after the company was notified by Novartis that it has chosen to terminate the agreement with Mesoblast prior to closing.

MESO

1 minute read

Mesoblast’s Heart Failure Candidate Shows Treatment Benefit In High-Risk Patients

By Vandana Singh

Today, 8:36 PM

Mesoblast Limited (NASDAQ: MESO)

MESO

3 minute read

News

Mesoblast Announced Rexlemestrocel-L Shows Greatest Treatment Benefit on Major Adverse Cardiovascular Events in High-Risk Heart Failure Patients With Diabetes and/or Myocardial Ischemia

By Charles Gross

Today, 8:36 PM

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided new analyses from the landmark DREAM-HF Phase 3 trial showing that the greatest treatment benefit from rexlemestrocel-L is in HFrEF patients with diabetes and/or ischemia, who are at high-risk of cardiovascular mortality, heart attacks or strokes.

MESO

1 minute read

Mesoblast’s Remestemcel Shows Promising Action In Patients With Heart Failure

By Vandana Singh

Today, 8:36 PM

Mesoblast Limited (NASDAQ:MESO) presented new results from the landmark Phase 3 study of rexlemestrocel-L in 565 patients with chronic heart failure…

MESO

2 minute read

Mesoblast Announced Remestemcel-L Improves Survival of Children With Biomarkers for Highest Mortality in Steroid Refractory Acute GVHD

By Charles Gross

Today, 8:36 PM

Mesoblast Limited (Nasdaq: MESO) announced that results published in the latest issue of the peer-reviewed journal Bone Marrow Transplantation1 showed that children with steroid-refractory acute graft versus host disease (SR-aGVHD) and biomarkers predictive for highest mortality had 64% survival when treated with remestemcel-L

MESO